Formulation And In Vivo Evaluation Of Ritonavir Nanosuspension

Article Sidebar

PDF
Published: Aug 25, 2023
DOI: https://doi.org/10.53555/jrtdd.v6i9s.2939
Keywords:
Ritonavir Nanosuspension Pharmacokinetic parameters.

Main Article Content

P.Bhaskar Reddy
C.K.Dhanapal
Shaik Harun Rasheed

Abstract

Aim: Formulation and in vivo evaluation of Ritonavir nanosuspension.


Objectives: To study the significance variance in the pharmacokinetic parameters of  ritonavir.


Methods: Blood samples were collected and studied for Pharmacokinetic parameters.


Results: It was observed that when compared to pure drug, nanosuspension had improved pharmacokinetic properties.


Conclusion: In the current study, the prepared NS have better bioavailability when compared to pure drug.

Article Details

How to Cite
P.Bhaskar Reddy, C.K.Dhanapal, & Shaik Harun Rasheed. (2023). Formulation And In Vivo Evaluation Of Ritonavir Nanosuspension. Journal for ReAttach Therapy and Developmental Diversities, 6(9s), 2006–2010. https://doi.org/10.53555/jrtdd.v6i9s.2939
Issue
Vol. 6 No. 9s (2023)
Section
Articles
Author Biographies

P.Bhaskar Reddy

Department of Pharmacy, Annamalai University, Chidambaram, Tamilnadu-608001, India.

C.K.Dhanapal

Department of Pharmacy, Annamalai University, Chidambaram, Tamilnadu-608001, India.

Shaik Harun Rasheed

Department of Pharmacy, Guru Nanak Institutions Technical Campus (Autonomous), School of Pharmacy, Ibrahimpatnam, Telangana-501 506, India.

References

Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl). 2015 Apr 8;7:95-104.

Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348(8):702–710.

Hruz PW. HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. Curr Opin HIV AIDS. 2008;3(6):660–665.

Weller IV, Williams IG. ABC of AIDS. Antiretroviral drugs. BMJ. 2001;322(7299):1410–1412.

Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS. 1998;12(6):F37–F39.

Kim JG, Shan L. Beyond Inhibition: A Novel Strategy of Targeting HIV-1 Protease to Eliminate Viral Reservoirs. Viruses. 2022 May 28;14(6):1179.

Huang L, Chen C. Understanding HIV-1 protease autoprocessing for novel therapeutic development. Future Med Chem. 2013 Jul;5(11):1215-29.

Weber IT, Wang Y-F, Harrison RW. HIV Protease: Historical Perspective and Current Research. Viruses. 2021; 13(5):839.

Wagner, R.N., Reed, J.C. & Chanda, S.K. HIV-1 protease cleaves the serine-threonine kinases RIPK1 and RIPK2. Retrovirology 12, 74 (2015).

Morris JB, Tisi DA, Tan DCT, Worthington JH. Development and Palatability Assessment of Norvir® (Ritonavir) 100 mg Powder for Pediatric Population. Int J Mol Sci. 2019 Apr 6;20(7):1718.

Kalvakuntla S, Deshpande M, Attari Z, Kunnatur B K. Preparation and Characterization of Nanosuspension of Aprepitant by H96 Process. Adv Pharm Bull. 2016 Mar;6(1):83-90.

Roldan TL, Li S, Guillon C, Heindel ND, Laskin JD, Lee IH, Gao D, Sinko PJ. Optimizing Nanosuspension Drug Release and Wound Healing Using a Design of Experiments Approach: Improving the Drug Delivery Potential of NDH-4338 for Treating Chemical Burns. Pharmaceutics. 2024 Mar 27;16(4):471.